Biological Optimization Versus Standard Care in Post-POEM Achalasia Patients (BIO-POEM)
Key facts
- Who runs it
- Asian Institute of Gastroenterology, India
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 166 people, planned
- Started
- 20 May 2026
- Expected to end
- 20 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Structured Biological Optimization
- Record updated
- 2 June 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Above criteria plus AET> 6% on pH impedance monitoring
- Adults aged 18-70 years
- Patients who stopped PPI/PCABs atleast 4 weeks prior to enrolment (to avoid false negative h.pylori test)
- Prior POEM performed between 6 months and 5 years before enrolment at AIG hospitals
- Willingness to comply with lifestyle and nutritional interventions
- Ability to provide written informed consent
- Adults aged 18-70 years
- Prior POEM performed between 6 months and 5 years before enrolment, at AIG hospitals
- Clinically significant GERD symptoms after POEM. GERD-HRQL score ≥10, or
- reflux symptoms occurring ≥3 times per week, or
- current use of PPI/PCAB therapy for reflux symptom control
- reflux esophagitis on endoscopy
- Unable to undergo ambulatory reflux monitoring due to logistical reasons,
- Ability to provide written informed consent
Who cannot take part
- Prior oesophageal surgery other than POEM
- Contraindication to PPI therapy
- Active gastrointestinal malignancy
- Severe comorbidities limiting life expectancy (<2 years)
- Pregnancy or lactation
- Inability to provide informed consent or comply with follow-up
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to evaluate whether a structured biological optimization program can improve reflux symptoms and overall recovery in patients with achalasia cardia who previously underwent Peroral Endoscopic Myotomy (POEM). Although POEM is highly effective for relieving swallowing difficulty, many patients develop gastroesophageal reflux disease (GERD) after the procedure and remain dependent on long-term acid suppressive medications such as proton pump inhibitors (PPIs).
Read full original descriptionShow less
The BIO-POEM study will compare structured biological optimization with standard post-POEM care in patients with objectively confirmed pathological reflux after POEM. The intervention includes reflux-oriented dietary counseling, micronutrient assessment and correction, Helicobacter pylori testing and eradication when indicated, lifestyle optimization, and structured review and tapering of PPI/PCAB therapy.
The study includes two components:
A randomized controlled trial enrolling post-POEM patients with objectively confirmed reflux.
A parallel prospective observational registry enrolling symptomatic post-POEM patients who are unable to undergo reflux testing or who remain symptomatic despite low acid exposure.
The primary objective is to determine whether structured biological optimization reduces GERD symptom burden at 12 months compared with standard care. Secondary objectives include evaluation of dyspepsia symptoms, nutritional recovery, quality of life, reduction in PPI dependence, and exploratory assessment of gut microbiome changes.
The 2 groups in the trial
- Structured Biological OptimizationTreatment being tested
Participants in this arm will receive a structured, protocol-driven biological optimization program in addition to standard post-POEM follow-up. The intervention includes reflux-oriented dietary counseling, lifestyle modification, micronutrient assessment and correction (including vitamin D, B12, iron, calcium, and pre-albumin where deficient), Helicobacter pylori testing and eradication where indicated, and a structured, stepwise de-escalation of proton pump inhibitor (PPI) or potassium-competitive acid blocker (PCAB) therapy based on clinical response and physician assessment.
- Standard Post-POEM CareExisting treatment, for comparison
Participants in this arm will receive routine post-POEM care as practiced at the study center. Management will be symptom-driven and may include proton pump inhibitor (PPI) or PCAB therapy as clinically indicated. No structured dietary, micronutrient, or deprescribing protocol will be applied beyond standard clinical practice. Follow-up assessments and outcome evaluations will be performed in the same manner as the intervention arm.
Treatment: Structured Biological Optimization
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Controlled Trial of Structured Biological Optimization Versus Standard Care With Embedded Prospective Registry in Post-POEM Achalasia Cardia Patients.
- Record updated
- 2 June 2026